Gary Maharaj Net Worth

The estimated Net Worth of Gary R Maharaj is at least $19.3 Million dollars as of 21 August 2024. Mr. Maharaj owns over 61,017 units of Surmodics stock worth over $9,931,114 and over the last 14 years he sold SRDX stock worth over $7,018,520. In addition, he makes $2,343,630 as President, Chief Executive Officer, and Director at Surmodics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Maharaj SRDX stock SEC Form 4 insiders trading

Gary has made over 39 trades of the Surmodics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 61,017 units of SRDX stock worth $2,025,764 on 21 August 2024.

The largest trade he's ever made was exercising 130,587 units of Surmodics stock on 23 August 2016 worth over $1,565,738. On average, Gary trades about 8,712 units every 46 days since 2010. As of 21 August 2024 he still owns at least 253,151 units of Surmodics stock.

You can see the complete history of Mr. Maharaj stock trades at the bottom of the page.

Gary Maharaj biography

Gary R. Maharaj serves as President, Chief Executive Officer, Director of the Company. Prior to joining the Company, Mr. Maharaj served as President and Chief Executive Officer of Arizant Inc., a provider of patient temperature management systems in hospital operating rooms, from 2006 to 2010. Previously, Mr. Maharaj served in several senior level management positions for Augustine Medical, Inc. (predecessor to Arizant Inc.) from 1996 to 2006, including Vice President of Marketing, and Vice President of Research and Development. During his 30 years in the medical device industry, Mr. Maharaj has also served in various management and research positions for the orthopedic implant and rehabilitation divisions of Smith & Nephew, PLC. He has been a director of NVE Corporation, a public technology company since 2014, and serves as a member of the audit committee and as a member of the compensation committee.

What is the salary of Gary Maharaj?

As the President, Chief Executive Officer, and Director of Surmodics, the total compensation of Gary Maharaj at Surmodics is $2,343,630. There are no executives at Surmodics getting paid more.

How old is Gary Maharaj?

Gary Maharaj is 56, he's been the President, Chief Executive Officer, and Director of Surmodics since 2010. There are 9 older and 9 younger executives at Surmodics. The oldest executive at Surmodics, Inc. is David Dantzker, 76, who is the Independent Director.

What's Gary Maharaj's mailing address?

Gary's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.

Insiders trading at Surmodics

Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj, and Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.

What does Surmodics do?

surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.

Complete history of Mr. Maharaj stock trades at NVE Corp and Surmodics

Surmodics executives and stock owners

Surmodics executives and other stock owners filed with the SEC include:

• Gary Maharaj,
  President, Chief Executive Officer, Director
• Gary R. Maharaj,
  CEO, Pres & Director
• Teri Sides,
  Senior Vice President, Chief Marketing Officer
• Charles Olson,
  Senior Vice President of Commercial and Business Development, Medical Devices
• Gregg Sutton,
  Vice President - Research and Development, Medical Devices
• Thomas Greaney,
  Chief Operating Officer, Medical Devices
• Timothy Arens,
  Chief Financial Officer, Vice President - Finance
• Joseph Stich,
  Vice President, General Manager - In Vitro Diagnostics
• Gordon S. Weber,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Timothy J. Arens,
  Sr. VP of Fin. & Information Technology and CFO
• Joseph J. Stich,
  Sr. VP and GM of HR & In Vitro Diagnostics
• Teryl L. W. Sides,
  Sr. VP of Product Devel. & Chief Marketing Officer
• Susan Knight,
  Non-Executive Independent Chairman of the Board
• Ronald Kalich,
  Independent Director
• David Dantzker,
  Independent Director
• Jose Bedoya,
  Independent Director
• Shawn McCormick,
  Independent Director
• Lisa Heine,
  Independent Director
• Nusrath Sultana,
  Vice President - Clinical Affairs
• Gordon Weber,
  Senior Vice President - Legal, General Counsel, Secretary
• Gregg S. Sutton,
  VP of R&D - Medical Devices
• Charles W. Olson,
  Sr. VP of Commercial & Bus. Devel. of Medical Devices
• John D. Manders,
  Corp. Controller & Principal Accounting Officer
• Lise W Duran,
  VP Product Development
• Andrew D. C. La Frence,
  VP of Finance & CFO
• Amy E. Seibert,
  Principal Accounting Officer
• Michael J Shoup,
  Vice President
• Douglas P Astry,
  General Manager
• Aron B Anderson,
  VP & Chief Scientific Officer
• John C. Middleton,
  VP, Drug Del, Product Dev
• Brian L Robey,
  Vice President
• Paul A Lopez,
  Vice President
• Bruce Barclay,
  President & COO
• John D. Manders,
  Corporate Controller
• Steven J Keough,
  VP & Chief IP Counsel
• Peter L Ginsberg,
  Vice President
• Bryan K Phillips,
  SVP, Gen Counsel & Secretary
• Kendrick B Melrose,
  Director
• David A Koch,
  Director
• Dale R Olseth,
  Chairman and CEO
• Loren R Miller,
  Vice President and Controller
• David S Wood,
  VP & GM - Drug Del. Bus. Unit
• Patrick E Guire,
  Senior Vice President
• Gregory T Yung,
  VP Sales & Business Developmen
• Ronald F Ofstead,
  VP Chemistry Development
• Richard C Carlson,
  VP of Strategic Planning
• Jane M Nichols,
  Vice President Marketing
• Marie J Versen,
  Vice President
• John W Benson,
  Director
• Mary K Brainerd,
  Director
• Mark A. Lehman,
  Treasurer
• Scott R. Ward,
  Director
• Gerald B Fischer,
  Director
• Timothy S Nelson,
  Director
• Robert C Buhrmaster,
  Director
• Eugene C. Rusch,
  VP, Manufacturing
• Value Lp Starboard Value Gp...,
  
• Philip D Ankeny,
  Chief Financial Officer
• Jeffrey C Smith,
  Director
• John A Meslow,
  Director
• Jan M Webster,
  Vice President, HR
• Arthur J Tipton,
  Vice President
• Kenneth H Keller,
  Director